{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:49:44Z","timestamp":1776232184724,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research on Rare and Intractable Diseases, Ministry of Health, Labour, and Welfare, Japan","award":["H29-nannti-ippann-018"],"award-info":[{"award-number":["H29-nannti-ippann-018"]}]},{"name":"Research on Rare and Intractable Diseases, Ministry of Health, Labour, and Welfare, Japan","award":["20FC1044"],"award-info":[{"award-number":["20FC1044"]}]},{"name":"Research on Rare and Intractable Diseases, Ministry of Health, Labour, and Welfare, Japan","award":["23FC1019"],"award-info":[{"award-number":["23FC1019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody-associated vasculitis causing multi-organ damage and long-term disability. Various treatments including IL-5-targeting agents and other biologics have recently emerged, prompting regular updates of clinical practice guidelines. This scoping review and systematic review (SR) aimed to evaluate the efficacy and safety of rituximab and benralizumab in EGPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted to identify relevant clinical questions, followed by an SR of trials published between December 2018 and July 2023. Studies comparing rituximab or benralizumab with standard treatments were included. Risk of bias (RoB) was assessed using RoB 2 and quality of evidence was rated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One randomised controlled trial (RCT; n\u2009=\u2009105) comparing rituximab with conventional therapy, showed a 180-day remission rate of 63.5% versus 60.4% (risk ratio: 1.05, 95% CI: 0.78\u20131.42), with very low certainty due to serious RoB and imprecision. Another RCT compared benralizumab with mepolizumab, showing similar rates of remission (58.6% versus 55.7%), relapse (30%), and glucocorticoid tapering, with low certainty owing to imprecision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rituximab showed no clear benefit over conventional therapy, whereas benralizumab demonstrated comparable efficacy and safety to mepolizumab. However, evidence remains limited, and further EGPA-specific trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf126","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:51:06Z","timestamp":1765889466000},"page":"415-421","source":"Crossref","is-referenced-by-count":0,"title":["Updated treatment approaches for eosinophilic granulomatosis with polyangiitis: A systematic scoping review"],"prefix":"10.1093","volume":"36","author":[{"given":"Mayu","family":"Shiomi","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kanazawa University , Kanazawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-0818","authenticated-orcid":false,"given":"Ken-ei","family":"Sada","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Kochi Medical School , Nankoku ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ome Medical Center , Ome ,","place":["Japan"]},{"name":"Department of Rheumatology, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Public Health, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University , Kanazawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University , Okayama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Sekiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital , Kanagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Kurasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University , Kawagoe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital , Chiba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University , Saga ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Komagata","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University , Kagawa ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-2954","authenticated-orcid":false,"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026041500565296200_ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026041500565296200_ref2","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1093\/rheumatology\/keae038","article-title":"Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: a survey of 312 patients","volume":"63","author":"Collins","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500565296200_ref3","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1007\/s12325-025-03197-5","article-title":"Reality of patient-reported symptoms in 200 patients with eosinophilic granulomatosis with polyangiitis: a cross-sectional survey (the KUNPU study)","volume":"42","author":"Amano","year":"2025","journal-title":"Adv Ther"},{"key":"2026041500565296200_ref4","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041500565296200_ref5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026041500565296200_ref6","doi-asserted-by":"crossref","first-page":"102737","DOI":"10.1016\/j.autrev.2020.102737","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review","volume":"20","author":"Akiyama","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2026041500565296200_ref7","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","article-title":"Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies","volume":"60","author":"Menditto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026041500565296200_ref8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026041500565296200_ref9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr2.11263","article-title":"Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America","volume":"3","author":"Doubelt","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026041500565296200_ref10","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"2026041500565296200_ref11","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.jviscsurg.2010.10.010","article-title":"Clinical practice guidelines","volume":"147","author":"Fervers","year":"2010","journal-title":"J Visc Surg"},{"key":"2026041500565296200_ref12","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026041500565296200_ref13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026041500565296200_ref14","first-page":"2021","volume-title":"Treatment Guide for Antiphospholipid Syndrome, Eosinophilic Granulomatosis with Polyangiitis, Polyarteritis Nodosa, and Rheumatoid Vasculitis 2020","author":"Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis"},{"key":"2026041500565296200_ref15","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 62 (Updated February 2022)","author":"Higgins","year":"2022"},{"key":"2026041500565296200_ref16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026041500565296200_ref17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/acr2.11571","article-title":"Clinical benefit of mepolizumab in eosinophilic granulomatosis with polyangiitis for patients with and without a vasculitic phenotype","volume":"5","author":"Terrier","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"2026041500565296200_ref18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026041500565296200_ref19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026041500565296200_ref20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026041500565296200_ref21","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2026041500565296200_ref22","doi-asserted-by":"crossref","first-page":"1204444","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/r\u03b1 biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"2026041500565296200_ref23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/rheumatology\/kead302","article-title":"Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study","volume":"63","author":"Milanesi","year":"2023","journal-title":"Rheumatology"},{"key":"2026041500565296200_ref24","doi-asserted-by":"crossref","DOI":"10.1093\/mr\/road001","article-title":"Evaluation of prognostic factors for patients with eosinophilic granulomatosis with polyangiitis recruited at pneumonological center and mainly ANCA-negative: a retrospective analysis of a single cohort in Poland","volume":"34","author":"Fijolek","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026041500565296200_ref25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-022-02845-3","article-title":"Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study","volume":"24","author":"Ueno","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026041500565296200_ref26","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","article-title":"Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology"},{"key":"2026041500565296200_ref27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3899\/jrheum.171352","article-title":"Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis","volume":"45","author":"Saku","year":"2018","journal-title":"J Rheumatol"},{"key":"2026041500565296200_ref28","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026041500565296200_ref29","first-page":"4135","article-title":"Rituximab versus conventional therapeutic strategy for remission-induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [abstract]","volume":"73(Suppl)","author":"Terrier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026041500565296200_ref30","volume-title":"Rituximab in Eosinophilic Granulomatosis with Polyangiitis (REOVAS)","author":"ClinicalTrials.gov"},{"key":"2026041500565296200_ref31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","article-title":"Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis: a randomized controlled trial: a randomized controlled trial","volume":"178","author":"Terrier","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026041500565296200_ref32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"2026041500565296200_ref33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2026041500565296200_ref34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026041500565296200_ref35","first-page":"S54","article-title":"Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life","volume":"34","author":"Pugnet","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2026041500565296200_ref36","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026041500565296200_ref37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026041500565296200_ref38","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2024.04.033","article-title":"MELTEMI and COLUMBA: 5-year comparative safety analysis of benralizumab and mepolizumab","volume":"12","author":"Bourdin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf126\/66097987\/roaf126.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/415\/66097987\/roaf126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/415\/66097987\/roaf126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:05Z","timestamp":1776229025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/415\/8400304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,22]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf126","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,12,22]]}}}